Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors

Psychosis and Schizophrenia

The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease

Expert Rev Neurother.

Hermanowicz S, Hermanowicz N

doi: 10.1586/

COMMENTED

Multiple Sclerosis

Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases

Read the related editorial recommended by Dr med. Andreas Hottinger: Parkinson Disease and Autoimmune Disorders-What Can We Learn From Genome-wide Pleiotropy?

doi: 10.1001/

Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease

Brain.

Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J; International Parkinson’s Disease Genomics Consortium (IPDGC), Heutink P, Shulman JM; IPDGC Consortium members; International Parkinson’s Disease Genomics Consortium (IPDGC)

doi: 10.1093/brain/awx285.

Anxiety and Depression

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease

J Parkinsons Dis.

Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C

doi: 10.3233/JPD-171143.

Parkinson’s Disease

β-adrenoreceptors and the risk of Parkinson's disease

Lancet Neurol.

Hopfner F, Höglinger GU, Kuhlenbäumer G, Pottegård A, Wod M, Christensen K, Tanner CM, Deuschl G

doi: 10.1016/S1474-4422(19)30400-4.

Parkinson’s Disease

Is Parkinson's disease a chronic low-grade inflammatory bowel disease?

J Neurol.

Rolli-Derkinderen M, Leclair-Visonneau L, Bourreille A, Coron E, Neunlist M, Derkinderen P

doi: 10.1007/s00415-

Parkinson’s Disease

Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson's disease

Neurobiol Dis.

Anidi C, O'Day JJ, Anderson RW, Afzal MF, Syrkin-Nikolau J, Velisar A, Bronte-Stewart HM

doi: 10.1016/j.nbd.2018.09.004.

RECOMMENDED

Parkinson’s Disease

Levodopa-induced dyskinesia in Parkinson disease: Current and Evolving Concepts

Ann Neurol.

Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE

doi: 10.1002/ana.25364.

Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores

Neurology.

Leehey M, Luo S, Sharma S, Wills AA, Bainbridge JL, Wong PS, Simon DK, Schneider J, Zhang Y, Pérez A, Dhall R, Christine CW, Singer C, Cambi F, Boyd JT

doi: 10.1212/

Related content

The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease

Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases

Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease

β-adrenoreceptors and the risk of Parkinson's disease

Is Parkinson's disease a chronic low-grade inflammatory bowel disease?

Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson's disease

Levodopa-induced dyskinesia in Parkinson disease: Current and Evolving Concepts

Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores